Belharra Therapeutics Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Genomics-Proteomics
- Molecular Diversity
- Drug Discovery Technologies
- Pharmaceuticals
- Vaccines
Latest on Belharra Therapeutics Inc.
Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign
Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected
Coya Therapeutics, Inc. launched the final biopharmaceutical initial public offering in the US in 2022 on 29 December, raising $15.25m from the sale of 3.05 million shares at $5 each, which brought t